BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT

Inclusion Criteria:

1. Patient has or is indicated for a de novo dual chamber pacemaker. Patient informedconsent must be obtained within 30 days prior to a planned de novo implant of aMedtronic Astra/Azure dual chamber pacemaker system or up to 365 days after

2. On a stable antihypertension treatment regimen with 1, 2, or 3 classes ofantihypertensive drugs

3. Office SBP ≥140 mmHg and <180 mmHg

4. Average 24-Hour aSBP ≥130 mmHg and <170 mmHg

Exclusion Criteria:

1. LVEF <50%

2. NYHA Class II-IV

3. History of cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 6 months

4. Myocardial infarction (MI) within 3 months

5. Prior percutaneous or surgical coronary, carotid, or endovascular interventionwithin 3 months

6. Persistent or permanent atrial fibrillation

7. Mitral valve regurgitation greater than grade 3

8. Aortic stenosis with a valve area less than 1.5 cm2

9. Has an active or prior device-based anti-hypertensive treatment (e.g., renaldenervation procedure, baroreflex activation therapy)

10. Has an existing active cardiac device or neurostimulator other than the recentAstra/Azure pacemaker implant